Increasing evidence continues to reinforce the notion of a wide-ranging phenomenon of extracellular HSP90 chaperoning, implicated in cancer progression and metastatic spread [12]–[16] thus supporting the development of inhibitors that specifically target the cell surface HSP90. The gene discussed is HSP90AA1; the disease is cancer.